Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
46.47 (USD) • At close March 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 94.819 | 224.947 | 71.66 | 171.332 | 168.129 | 57.952 | 2.355 |
| Short Term Investments
| 196.557 | 2.495 | 145.366 | 0.483 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 291.376 | 227.442 | 217.026 | 171.815 | 168.129 | 57.952 | 2.355 |
| Net Receivables
| 48.059 | 17.714 | 3.582 | 0.092 | 0.02 | 0.036 | 0.004 |
| Inventory
| 2.62 | 3.107 | 4.762 | 0 | 0 | 0.02 | 0 |
| Other Current Assets
| 14.65 | 7.868 | 4.767 | 8.09 | 2.506 | 0.022 | 0.024 |
| Total Current Assets
| 356.705 | 256.131 | 225.375 | 175.952 | 170.655 | 58.03 | 2.383 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 2.866 | 3.348 | 1.532 | 1.829 | 1.236 | 0.28 | 0.006 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 8.326 | 3.867 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 8.326 | 3.867 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 3 | 0.631 | 0.371 | 0.663 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 6.094 | 1.514 | 0.585 | 0.463 | 0.081 | 0.006 | 0 |
| Total Non-Current Assets
| 20.286 | 9.36 | 2.488 | 2.955 | 1.317 | 0.286 | 0.006 |
| Total Assets
| 376.991 | 265.491 | 227.863 | 178.907 | 171.972 | 58.316 | 2.389 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 27.739 | 18.149 | 5.498 | 2.856 | 2.237 | 0.456 | 0.175 |
| Short Term Debt
| 0.608 | 0.398 | 0.721 | 1.306 | 0.282 | 0.064 | 0 |
| Tax Payables
| 0 | 0 | 0.014 | 0.055 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 0 | 0 | 0.697 | 0 | 0 | 0 |
| Other Current Liabilities
| 52.265 | 18.389 | 9.196 | 7.261 | 2.868 | 0.299 | 0.004 |
| Total Current Liabilities
| 80.612 | 36.936 | 15.429 | 11.478 | 5.387 | 0.819 | 0.179 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 71.845 | 31.334 | 19.434 | 0.585 | 0.549 | 0.1 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0 | 0.233 | 0.1 | 0.114 | 0.056 | 63.402 | 3.564 |
| Total Non-Current Liabilities
| 71.845 | 31.567 | 19.534 | 0.699 | 0.605 | 63.502 | 3.564 |
| Total Liabilities
| 152.457 | 68.503 | 34.963 | 12.177 | 5.992 | 64.321 | 3.743 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 171.972 | 63.402 | 3.564 |
| Common Stock
| 0.006 | 0.005 | 0.005 | 0.004 | 0.004 | 0.002 | 0.001 |
| Retained Earnings
| -360.21 | -244.656 | -108.763 | -46.672 | -32.845 | -6.034 | -1.364 |
| Accumulated Other Comprehensive Income/Loss
| 0.179 | -0.002 | -0.074 | 0 | -171.972 | -63.402 | -0.001 |
| Other Total Stockholders Equity
| 584.559 | 441.641 | 301.732 | 213.398 | 198.821 | 0.027 | -3.563 |
| Total Shareholders Equity
| 224.534 | 196.988 | 192.9 | 166.73 | 165.98 | -6.005 | -1.354 |
| Total Equity
| 224.534 | 196.988 | 192.9 | 166.73 | 165.98 | -6.005 | -1.354 |
| Total Liabilities & Shareholders Equity
| 376.991 | 265.491 | 227.863 | 178.907 | 171.972 | 58.316 | 2.389 |